Jaxon Quillen

Jaxon Quillen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CBCaitlin M. Brumfiel
Caitlin M. Brumfiel
MPMeera H. Patel
Meera H. Patel
KSKevin J. Severson
Kevin J. Severson
NZNan Zhang
Nan Zhang
XLXing Li
Xing Li
AMAaron R. Mangold
Aaron R. Mangold

Verified
Journal Article
Open access
PDF file
NENouran Eshak
Nouran Eshak
MAMahmoud Abdelnabi
Mahmoud Abdelnabi
JQJaxon Quillen
Jaxon Quillen
MPMicheal Pham
Micheal Pham
JHJoseph Hentz
Joseph Hentz
VNVivek Nagaraja
Vivek Nagaraja
Introduction: Cardiac involvement in patients with systemic sclerosis (SSc) can present variably from being asymptomatic to manifesting with heart failure, conduction abnormalities, pulmonary hypertension, and pericardial effusion. Symptomatic cardiac involvement portends a poor prognosis and worse overall survival. Sacubitril/valsartan (SV), an angiotensin receptor neprilysin inhibitor, has been shown to significantly reduce hospitalization rates and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the effects of SV treatment in patients with SSc and heart failure. Methods: A retrospective analysis of patients with SSc was conducted using an electronic data capture tool. Patients with SSc treated with SV between January 2015 and August 2023 were identified. Comprehensive clinical phenotyping and longitudinal data analysis were performed to characterize the sub-type of patients and evaluate clinical outcomes, including hospitalizations and mortality, laboratory markers, and echocardiographic findings. Results: Twenty-four patients with SSc were treated with SV for a mean duration of 20.6 months. HFrEF was the primary indication for SV use in 91% of patients, primarily due to non-ischemic cardiomyopathy (87.5%). There was a significant reduction in systolic blood pressure from 128 mmHg to 114 mmHg (p < 0.001) and NT-proBNP levels from 15,130 pg/mL to 5082 pg/mL (p = 0.046). In the 19 patients with baseline and follow-up echocardiograms, there was a significant improvement in LVEF from 40.3% to 47.7% (p = 0.014). Hypotension was a common side effect leading to discontinuation of SV (n = 4, 16.7%). Serum creatinine had trends of improvement (1.9 mg/dL to 1.3 mg/d), though it did not reach statistical significance (p = 0.057). Conclusions: This study showed that SV effectively improved cardiac symptoms and function in patients with SSc presenting with HFrEF. Further prospective studies are needed to confirm these findings and explore the role of SV in the treatment of other manifestations of SSc.

28 September 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
JAJessica Danielle Austin
Jessica Danielle Austin
Ilyse Arielle NelsonIlyse Arielle Nelson
Ilyse Arielle Nelson
JTJon C. Tilburt
Jon C. Tilburt
EEEric Ellinghysen
Eric Ellinghysen
CYClaire Ida Yee
Claire Ida Yee
SMSteven W. Ressler MD
Steven W. Ressler MD
Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.

9 April 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
DIDan Ilges
Dan Ilges
KJKelsey Jensen
Kelsey Jensen
EDEvan Draper
Evan Draper
ETEmily Thompson
Emily Thompson
JQJaxon Quillen
Jaxon Quillen
RSRyan W. Stevens
Ryan W. Stevens
Background: Outpatient antibiotic stewardship programs (ASP) are recommended by the CDC and Joint Commission. We analyzed the impact of annual, focused syndrome-specific ASP interventions on trends in long-duration antibiotic prescribing (LDAP). Methods: This was a retrospective, observational, multicenter cohort study from November 2020 through June 2025. All ambulatory encounters generating systemic antibiotic prescriptions within the healthcare enterprise were screened. Hospitalizations, emergency department visits, and infectious diseases encounters were excluded. Encounters generating ≥1 systemic antibiotic with >7 days duration were categorized as long-duration. Targeted departments (primary and urgent care) received direct intervention (e.g., education, peer-comparison reporting, data tracking). LDAP was modeled over time by month and compared by diagnosis group (ASP-priority diagnoses vs non-priority) and provider specialty department (ASP-targeted vs non-targeted) using linear regression models. Results: Of 642,579 encounters included, 42.2% were long duration. LDAP in ASP-targeted departments dropped from 46.8% to 34.8% (difference -12 percentage points [pp]), whereas non-targeted departments dropped from 45.5% to 39.1% (difference -6.4pp). The estimated annual LDAP decrease was 3.4 pp in targeted vs 2.4 pp in non-targeted departments (difference 1.0 pp, P=0.009). Within targeted departments, significant LDAP decreases were seen both in priority and non-priority diagnoses, whereas non-targeted departments showed no change in LDAP in priority diagnoses. In a sensitivity analysis of non-priority diagnoses, ASP-targeted departments had a larger estimated annual decrease vs non-targeted (difference 1.4 pp, P<0.001). Conclusions: Annual syndrome-specific ASP interventions correlated with improvements in LDAP, including outside of priority syndromes in targeted departments. LDAP is a viable metric for evaluating ambulatory ASPs.

3 July 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JSJamilah Shubeilat
Jamilah Shubeilat
SNSandhya Nagarakanti
Sandhya Nagarakanti
AAAbeer Almajali
Abeer Almajali
JQJaxon Quillen
Jaxon Quillen
MBMatthew R Buras
Matthew R Buras
JBJanis Blair
Janis Blair
Peritoneal coccidioidomycosis is a rare, disseminated manifestation of Coccidioides infection with limited representation in the literature. We report 37 proven or probable cases from a single institution, including 12 patients (32%) with immunosuppression. Thirty-six patients received antifungal therapy, all of whom demonstrated clinical response. Among 11 (29.7%) patients who completed and stopped therapy after a median duration of 26 months, 2 (5%) experienced a relapse and were successfully retreated. Nine patients (24%) had no known relapse. Thirteen patients (35%) required modification of antifungal regimens, primarily due to azole adverse effects. Treatment approaches and median duration of therapy (57 months) were similar between immunosuppressed and non-immunosuppressed groups. No deaths were attributable to infection. Overall, outcomes were favorable, with strong clinical responses to azole therapy. Patients without identifiable immunologic deficits or additional sites of dissemination, when managed with antifungal therapy and close clinical, radiologic, and serologic monitoring, may achieve good prognosis, particularly when indefinite azole therapy is not feasible.

5 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EEEvrim Erdemogľu
Evrim Erdemogľu
KRKathryn J. Ruddy
Kathryn J. Ruddy
MBMatthew R Buras
Matthew R Buras
JQJaxon Quillen
Jaxon Quillen
FCFergus J. Couch
Fergus J. Couch
KBKristina A Butler
Kristina A Butler
Background/Objectives: This study aims to evaluate the quality of life (QoL) and oncological outcomes in premenopausal women diagnosed with hormone receptor-positive breast cancer who are receiving either bilateral oophorectomy (BO) or gonadotropin-releasing hormone agonist (GnRH) therapy. Both methods serve to inhibit ovarian function, which is essential for the management of estrogen-dependent tumors; however, their effects on QoL have yet to be fully clarified. Methods: Data were analyzed from the Mayo Clinic Breast Disease Registry, focusing on women under 55 diagnosed with estrogen receptor-positive breast cancer who received either BO or GnRH within one year of diagnosis. QoL was assessed using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) at baseline and annually for five years. Results: A total of 181 patients were enrolled in the study; 40 into the BO group and 141 to the GnRH group. Both groups exhibited similar levels of sexual dysfunction after a one-year period; however, the BO group stated a higher frequency of hot flashes. PROMIS-10 scores improved in both mental and physical health over time, with no significant differences between the groups. Within the BO group, one recurrence was observed, in contrast to the GnRH group, which had six events. Nonetheless, the difference in recurrence rates did not reach statistical significance. Conclusions: The long-term QoL and oncologic outcomes for premenopausal women with hormone receptor-positive breast cancer were similar for BO and GnRH therapy. These findings emphasize the need for individualized treatment decisions, considering patient preferences and side effects.